New Novo-studies to identify the link between cardiovascular disease and diabetes
Novo Nordisk aims to register the occurrence of cardiovascular disease among type 2 diabetes patients in a new study with 8000 participants from ten different countries. At the same time, the drug group is enrolling Portuguese patients in a similar, but smaller, trial. Both studies are part of the company's venture into new disease areas.
During the years, the connection between diabetes, obesity and the risk of developing cardiovascular disease has become more and more evident.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
